Trials / Unknown
UnknownNCT03858387
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of β-lactams in Critically Ill Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (estimated)
- Sponsor
- Prince of Songkla University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Meropenem and imipenem are broad-spectrum carbapenem antibiotic and are frequently prescribed in critically ill patients with severe infections. These patients show several pathophysiological changes that may alter the carbapenem pharmacokinetic (PK) normally found in other populations. Although the PK of carbapenems has been widely studied, most studies have been conducted on small populations, and clinical outcome data are sparse. Therefore, the aims of this study are (i) describe the population pharmacokinetic parameters of meropenem and imipenem in critically ill subject (ii) evaluate the pharmacodynamic of meropenem and imipenem as a predictor of clinical treatment outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Meropenem | This group is composed of 52 critically ill patients, meropenem dosage is chosen by the intensivist in charge of the case. Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2.5 h, 2.5-4 h, 4-8 h or 4-12 after meropenem administration. |
| DRUG | Imipenem | This group is composed of 50 critically ill patients, imipenem dosage is chosen by the intensivist in charge of the case. Blood sampling: 5 blood samples (3 mL) were obtained from a heparinized intravascular catheter by direct venipuncture at the following time: before (time 0) and during 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h or 4-12 after imipenem administration. |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
- First posted
- 2019-02-28
- Last updated
- 2020-05-01
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03858387. Inclusion in this directory is not an endorsement.